In short
Teriflunomide, marketed under the brand name Aubagio, is an oral medication that has shown promise in the treatment of multiple sclerosis (MS) and other autoimmune conditions. This article explores the use of teriflunomide in various clinical trials, examining its efficacy, safety, and potential benefits for patients with relapsing forms of MS and other disorders.
At a glance
- Primary Conditions Studied
- Relapsing-Remitting Multiple Sclerosis (RRMS), HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), Immune Thrombocytopenia
- Dosage
- Typically 7 mg or 14 mg oral tablets, administered daily
- Primary Outcomes Measured
- Reduction in MS relapses, changes in MRI lesions, disability progression (EDSS scores), patient-reported outcomes, safety and tolerability
- Secondary Outcomes
- Quality of life measures, cognitive function, biomarker analysis, long-term safety and efficacy
- Study Designs
- Phase II and IV trials, observational studies, open-label studies, single-arm studies
- Duration of Studies
- Ranging from 24 weeks to 2 years, with some long-term extension studies
- Key Safety Monitoring
- Liver function tests, complete blood count, adverse event reporting
What is Teriflunomide?
Teriflunomide is a medication used to treat certain types of multiple sclerosis (MS). It's also known by its brand name Aubagio. Teriflunomide is the primary metabolite (breakdown product) of another drug called leflunomide, which is used to treat rheumatoid arthritis.
What Conditions Does Teriflunomide Treat?
Teriflunomide is primarily used to treat relapsing forms of multiple sclerosis (MS), including: Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery. Active Secondary Progressive Multiple Sclerosis (SPMS): A form of MS that can develop in some people with RRMS, where disability progressively worsens. Interestingly, research is also being conducted to explore the potential use of teriflunomide in treating other conditions, such as: HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A rare neurological condition caused by a virus. Immune Thrombocytopenia: A blood disorder characterized by a low platelet count.
How Does Teriflunomide Work?
Teriflunomide works by modulating (adjusting) the immune system. Specifically, it: Inhibits an enzyme called dihydroorotate dehydrogenase (DHODH): This enzyme is crucial for the rapid growth of certain immune cells (lymphocytes) that are involved in MS. Reduces inflammation: By limiting the growth of certain immune cells, teriflunomide helps reduce the inflammation that damages nerve cells in MS. Affects T-cell and B-cell function: These are types of white blood cells involved in the immune response. Teriflunomide may alter their behavior, which could contribute to its therapeutic effects. By these mechanisms, teriflunomide helps to slow down the progression of MS and reduce the frequency of relapses.
How is Teriflunomide Administered?
Teriflunomide is taken orally (by mouth) as a tablet. The typical dosage is: 14 mg once daily: This is the most common dose for adults with relapsing forms of MS. 7 mg once daily: This dose may be used in some cases, particularly if there are concerns about side effects. It's important to take teriflunomide exactly as prescribed by your healthcare provider. The medication is usually taken long-term to manage MS effectively.
Efficacy of Teriflunomide
Clinical trials have shown that teriflunomide can be effective in managing relapsing forms of MS. Some key findings include: Reduced relapse rate: Teriflunomide has been shown to lower the number of MS relapses patients experience. Slowed disability progression: Some studies have found that teriflunomide can slow the worsening of disability in MS patients. Reduced MRI activity: Teriflunomide has been shown to reduce the number of new or enlarging brain lesions seen on MRI scans. It's important to note that the effectiveness can vary from person to person, and your healthcare provider will monitor your response to the medication.
Side Effects and Safety
Like all medications, teriflunomide can cause side effects. Common side effects may include: Headache Diarrhea Nausea Hair thinning or hair loss Elevated liver enzymes More serious side effects, though less common, can include: Liver problems Low white blood cell count, which can increase the risk of infections High blood pressure Your healthcare provider will monitor you closely for these side effects through regular check-ups and blood tests. It's crucial to report any unusual symptoms or side effects to your doctor promptly.
Impact on Quality of Life
Several studies have looked at how teriflunomide affects patients' quality of life. Findings suggest that: Improved daily activities: Some patients report improvements in their ability to perform daily activities. Convenience: As an oral medication, teriflunomide may be more convenient for some patients compared to injectable MS treatments. Fatigue management: Some studies have examined teriflunomide's impact on MS-related fatigue, which is a common and debilitating symptom. However, experiences can vary, and it's important to discuss your personal goals and concerns with your healthcare provider.
Ongoing Research
Research on teriflunomide is ongoing, with scientists exploring: Long-term effects: Studies are looking at the long-term safety and efficacy of teriflunomide in MS patients. Biomarkers: Researchers are investigating whether certain biological markers can predict how well a patient will respond to teriflunomide. Use in other conditions: As mentioned earlier, teriflunomide is being studied for potential use in conditions other than MS. These ongoing studies may provide more insights into how teriflunomide works and how it can be used most effectively to help patients with MS and potentially other conditions.